News & Filings

Toolkit

Subscribe
RSS Feeds
Contact IR
Presentations

Sub Nav News & Filings

Press Releases

SEC Filings

Annual Reports and AGM

Quarterly Results

News & Filings

Year

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Apr 18, 2024

Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both high-risk (hr)HPV (60%, Group 2) and cervical lesions (67%,Groups 2 and 5), were observed in the

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Mar 20, 2024

OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the Company’s progress. Barinthus Bio is a clinical-stage biopharmaceutical

Cancer Research UK and VOLT open squamous oesophageal cancer cohort in immunotherapeutic trial

Mar 11, 2024

OXFORD and LONDON, UK, 11 March 2024 – Cancer Research UK’s Centre for Drug Development and Vaccitech Oncology Limited (VOLT), a strategic collaboration between Barinthus Biotherapeutics Plc and the Ludwig Institute for Cancer Research, have opened a new cohort in the Phase 1/2a MAGE clinical trial

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Jan 05, 2024

Cash runway anticipated to be extended from Q2 2025 to Q4 2025 Data from multiple Phase 1 and 2 clinical trials expected in 2024 OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial